Abeona Therapeutics Inc vs Cipher Mining Inc — how do they compare? Abeona Therapeutics Inc trades at $7.44 (market cap $421.19M), while Cipher Mining Inc trades at $17.91 (market cap $7.14B). The key difference: Cipher Mining Inc is far larger — about 17× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Cipher Mining Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CIFR | |
|---|---|---|
Market Cap | $421.19M | $7.14B |
Sector | Health | Basic Materials |
52-Week High | $7.45 | $29.18 |
52-Week Low | $4.17 | $4.72 |
Enterprise Value | $276.10M | $11.90B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
CIFR trades at $17.74, up 8.63% in the last session, but remains in a bearish technical trend with key support at $16. The company is transitioning from Bitcoin mining to AI data centers, reporting a Q2 2026 loss per share of $0.65, missing estimates. Revenue was $224 million in 2025 but fell to $191 million in 2026, with a net loss widening to $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target.
The outlook hinges on successful execution of its AI infrastructure pivot, offering growth potential but carrying high risk due to persistent losses, heavy capital expenditure, and reliance on project financing. Investors face volatility from operational cash burn and competitive pressures in the data center market, warranting caution despite optimistic Wall Street ratings.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →